Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Beilstein J Org Chem ; 12: 1765-71, 2016.
Article in English | MEDLINE | ID: mdl-27559421

ABSTRACT

The C8'-epimeric pyranosyl amino acid core 2 of amipurimycin was synthesized from D-glucose derived alcohol 3 in 13 steps and 14% overall yield. Thus, the Sharpless asymmetric epoxidation of allyl alcohol 7 followed by trimethyl borate mediated regio-selective oxirane ring opening with azide, afforded azido diol 10. The acid-catalyzed 1,2-acetonide ring opening in 10 concomitantly led to the formation of the pyranose ring skeleton to give 2,7-dioxabicyclo[3.2.1]octane 12. Functional group manipulation in 12 gave 21 that on stereoselective ß-glycosylation afforded the pyranosyl thymine nucleoside 2 - a core of amipurimycin.

2.
J Nanosci Nanotechnol ; 15(12): 9464-72, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26682367

ABSTRACT

Iron oxide nanoparticles (IONPs) have gained immense importance recently as drug nanocarriers due to easy multifunctionalization, simultaneous targeting, imaging and cancer hyperthermia. Herein, we report a novel nanomedicine comprising of IONPs core functionalized with a potent anticancer bioactive principle, diosgenin from medicinal plant Dioscorea bulbifera via citric acid linker molecule. IONPs were synthesized by reverse co-precipitation and characterized using field emission scanning electron microscopy (FESEM), high resolution transmission electron microscopy (HRTEM) and dynamic light scattering (DLS). Diosgenin functionalization was confirmed using fourier transform infrared spectroscopy (FTIR) and biochemical methods. Synthesized IONPs, citrate linked IONPs (IONPs-CA), diosgenin functionalized IONPs (IONPs-D) along with free citric acid and diosgenin were checked for anticancer activity against MCF7 breast cancer cells by MTT assay, wound migration assay, confocal microscopy and protein expression by western blotting. Size of IONPs, IONPs-CA and IONPs-D gradually increased ranging from 12 to 21 nm as confirmed by FESEM and HRTEM. Signature peaks of diosgenin at 2914, 1166 and 1444 cm-1 IONPs-D, revealed in FTIR indicated the presence of functionalized diosgenin. IONPs-D exhibited 51.08 ± 0.37% antiproliferative activity against MCF7 cells, which was found to be superior to free citric acid (17.71 ± 0.58%) and diosgenin (33.31 ± 0.37%). Treatment with IONPs-D exhibited reduced wound migration upto 40.83 ± 2.91% compared to bare IONPs (89.03 ± 2.58%) and IONPs-CA (50.35 ± 0.48%). IONPs-D and diosgenin exhibited apoptosis induction, confirmed by Alexa Fluor 488 annexin V/PI double-stained cells indicating extensive cell membrane damage coupled with PI influx leading to nuclear staining in treated cells. IONPs-D mediated selective PARP cleavage strongly rationalized it as superior apoptotic inducers. Based on these findings, IONPs-D can be considered as first diosgenin functionalized novel magnetic nanomedicine with antiproliferative, migration inhibiting and apoptosis inducing properties against breast cancer.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Breast Neoplasms/drug therapy , Diosgenin/pharmacology , Drug Carriers/chemistry , Magnetite Nanoparticles/chemistry , Humans , MCF-7 Cells
3.
Bioorg Med Chem ; 22(21): 5776-82, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-25305010

ABSTRACT

An efficient and practical strategy for the synthesis of (3R,4s,5S)-4-(2-hydroxyethyl) piperidine-3,4,5-triol and its N-alkyl derivatives 8a-f, starting from the D-glucose, is reported. The chiral pool methodology involves preparation of the C-3-allyl-α-D-ribofuranodialdose 10, which was converted to the C-5-amino derivative 11 by reductive amination. The presence of C-3-allyl group gives an easy access to the requisite hydroxyethyl substituted compound 13. Intramolecular reductive aminocyclization of C-5 amino group with C-1 aldehyde provided the γ-hydroxyethyl substituted piperidine iminosugar 8a that was N-alkylated to get N-alkyl derivatives 8b-f. Iminosugars 8a-f were screened against glycosidase enzymes. Amongst synthetic N-alkylated iminosugars, 8b and 8c were found to be α-galactosidase inhibitors while 8d and 8e were selective and moderate α-mannosidase inhibitors. In addition, immunomodulatory activity of compounds 8a-f was examined. These results were substantiated by molecular docking studies using AUTODOCK 4.2 programme.


Subject(s)
Enzyme Inhibitors/chemistry , Imino Sugars/chemistry , Immunosuppressive Agents/chemistry , Piperidines/chemistry , alpha-Galactosidase/antagonists & inhibitors , Alkylation , Binding Sites , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Humans , Imino Sugars/chemical synthesis , Imino Sugars/pharmacology , Immunosuppressive Agents/chemical synthesis , Immunosuppressive Agents/pharmacology , Jurkat Cells , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Molecular Docking Simulation , Protein Structure, Tertiary , alpha-Galactosidase/metabolism
4.
PLoS One ; 9(9): e106039, 2014.
Article in English | MEDLINE | ID: mdl-25216353

ABSTRACT

Diabetes mellitus is a multifactorial metabolic disease characterized by post-prandial hyperglycemia (PPHG). α-amylase and α-glucosidase inhibitors aim to explore novel therapeutic agents. Herein we report the promises of Dioscorea bulbifera and its bioactive principle, diosgenin as novel α-amylase and α-glucosidase inhibitor. Among petroleum ether, ethyl acetate, methanol and 70% ethanol (v/v) extracts of bulbs of D. bulbifera, ethyl acetate extract showed highest inhibition upto 72.06 ± 0.51% and 82.64 ± 2.32% against α-amylase and α-glucosidase respectively. GC-TOF-MS analysis of ethyl acetate extract indicated presence of high diosgenin content. Diosgenin was isolated and identified by FTIR, 1H NMR and 13C NMR and confirmed by HPLC which showed an α-amylase and α-glucosidase inhibition upto 70.94 ± 1.24% and 81.71 ± 3.39%, respectively. Kinetic studies confirmed the uncompetitive mode of binding of diosgenin to α-amylase indicated by lowering of both Km and Vm. Interaction studies revealed the quenching of intrinsic fluorescence of α-amylase in presence of diosgenin. Similarly, circular dichroism spectrometry showed diminished negative humped peaks at 208 nm and 222 nm. Molecular docking indicated hydrogen bonding between carboxyl group of Asp300, while hydrophobic interactions between Tyr62, Trp58, Trp59, Val163, His305 and Gln63 residues of α-amylase. Diosgenin interacted with two catalytic residues (Asp352 and Glu411) from α-glucosidase. This is the first report of its kind that provides an intense scientific rationale for use of diosgenin as novel drug candidate for type II diabetes mellitus.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/enzymology , Dioscorea/chemistry , Diosgenin/therapeutic use , Enzyme Inhibitors/therapeutic use , alpha-Amylases/antagonists & inhibitors , alpha-Glucosidases/metabolism , Animals , Catalytic Domain , Circular Dichroism , Diabetes Mellitus, Experimental/pathology , Diosgenin/chemistry , Diosgenin/pharmacology , Enzyme Inhibitors/isolation & purification , Enzyme Inhibitors/pharmacology , Intestines/enzymology , Kinetics , Mice , Molecular Docking Simulation , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Protein Binding/drug effects , Spectrometry, Fluorescence , Sus scrofa , alpha-Amylases/metabolism
5.
J Org Chem ; 79(10): 4398-404, 2014 May 16.
Article in English | MEDLINE | ID: mdl-24735108

ABSTRACT

We report herein a newly developed domino reaction that facilitates the synthesis of new 1,5-dideoxy-1,5-iminoribitol iminosugar C-glycosides 7a-e and 8. The key intermediate in this approach is a six-membered cyclic sugar nitrone that is generated in situ and trapped by an alkene dipolarophile via a [2 + 3] cycloaddition reaction to give the corresponding isooxazolidines 10a-e in a "one-pot" protocol. The iminoribitol C-glycosides 7a-e and 8 were found to be modest ß-galactosidase (bGal) inhibitors. However, compounds 7c and 7e showed "pharmacological chaperone" activity for mutant lysosomal bGal activity and facilitated its recovery in GM1 gangliosidosis patient fibroblasts by 2-6-fold.


Subject(s)
Alkenes/chemistry , Fibroblasts/chemistry , Gangliosidosis, GM1/drug therapy , Lysosomes/chemistry , Molecular Chaperones/pharmacology , Molecular Chaperones/therapeutic use , Monosaccharides/chemical synthesis , Nitrogen Oxides/chemistry , beta-Galactosidase/antagonists & inhibitors , beta-Galactosidase/chemistry , Cycloaddition Reaction , Gangliosidosis, GM1/enzymology , Gangliosidosis, GM1/metabolism , Glycosides , Humans , Lysosomes/metabolism , Monosaccharides/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...